Rapid response of advanced squamous non-small cell lung cancer with thrombocytopenia after first-line treatment with pembrolizumab plus autologous cytokine-induced killer cells
We present the first clinical evidence of advanced squamous non-small cell lung cancer with severe thrombocytopenia showing dramatic improvement after first-line treatment with pembrolizumab plus cytokine-induced killer cells.
Main Authors: | Zhenzhen eHui, Xinwei eZhang, Baozhu eRen, Runmei eLi, Xiubao eRen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2015-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2015.00633/full |
Similar Items
-
The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
by: Meng‐Jia Song, et al.
Published: (2021-01-01) -
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
by: Xin Li, et al.
Published: (2018-01-01) -
Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
by: Chau V, et al.
Published: (2020-08-01) -
Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
by: Vachhani P, et al.
Published: (2016-09-01) -
Unraveling Natural Killer T-Cells Development
by: Sabrina Bianca Bennstein
Published: (2018-01-01)